Contractor Advisory Committee (CAC) - JE Part A
Contractor Advisory Committee (CAC)
On this page, view the below CAC related information.
Per CMS Internet Only Manual (IOM), Publication 100-08, Medicare Program Integrity Manual, Chapter 13.2.4.3, "The purpose of the CAC is to provide a formal mechanism for healthcare professionals to be informed of the evidence used in developing the LCD and promote communications between the MAC and the healthcare community. CAC members should serve in an advisory capacity as representatives of their constituency to review the quality of the evidence used in the development of an LCD. The CAC is advisory in nature, with the final decision on all issues resting with MACs. Accordingly, the advice rendered by the CAC is most useful when it results from a process of full scientific inquiry and thoughtful discussion with careful framing of recommendations and clear identification of the basis of those recommendations."
Noridian may host a CAC meeting for subject matter expert consultation regarding published literature in the development of a proposed Local Coverage Determination (LCD). CAC panel members serve in an advisory capacity as representatives of their constituency to review the quality of the evidence used in the development of an LCD. The CAC is advisory in nature, with the final decision on all issues resting with MACs. Accordingly, the advice rendered by the CAC is most useful when it results from a process of full scientific inquiry and thoughtful discussion with careful framing of recommendations and clear identification of the basis of those recommendations. Participation in the CAC is voluntary.
Noridian does not provide an honorarium or other forms of compensation to members.
All CAC meetings will be open to the public to attend and observe.
Upcoming Meetings and Related Documents
Meetings occur as needed for the development of LCDs. Non-CAC members may participate in listen-only mode via teleconference.
There are currently no scheduled meetings.
Previous Meetings and Related Documents
| Date | Topic | Meeting Documents | Recordings |
|---|---|---|---|
| 11/12/2025 | Implantation of Anterior Segment Intraocular Nonbiodegradable Drug-eluting System | ||
| 09/04/25 | Multi-Jurisdictional CAC: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia | ||
| 08/20/25 | Coronary Intravascular Lithotripsy (IVL) | ||
| 02/03/25 | Peripheral Nerve Blocks | ||
| 10/17/24 | Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) | ||
| 07/15/24 | MolDX: Biomarker Risk Stratification Testing in DCIS | ||
| 10/19/23 | Botulinum Toxins | ||
| 08/16/23 | Cervical Fusion | ||
| 05/25/23 | Non-Invasive Technology for Coronary Artery Plaque Analysis | ||
| 04/27/23 | Trigger Point Injections | ||
| 02/28/23 | Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) for Non-implantable Devices | ||
| 01/05/23 | Micro-Invasive Glaucoma Surgery (MIGS) | ||
| 11/17/22 | Molecular Diagnostic Testing for Acute Rejection in Heart or Lung Allografts | ||
| 11/16/22 | Molecular Diagnostic Testing for Acute Rejection in Kidney or Liver Allografts | ||
| 03/10/22 | Multi-Jurisdictional Contractor Advisory Committee (CAC) for Sacroiliac Joint Injections and Procedures | ||
| 12/07/21 | MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis CAC Meeting | ||
| 10/12/21 | MolDX: Molecular Testing for Risk Stratification of Upper Gastrointestinal Cancer | ||
| 05/12/21 | Amniotic Product Injections for Musculoskeletal Indications, Non-Wound | ||
| 02/11/21 | Epidural Interventions for Chronic Pain Management | ||
| 01/11/21 | Molecular Diagnostic Panel Testing for Pathogens | ||
| 05/28/20 | Facet Joint and Medial Nerve Branch Procedures | ||
| 04/28/20 | Wound Care and Skin Substitutes | ||
| 11/12/19 | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia | ||
| 06/29/19 | Pharmagenomics | ||
| 06/18/19 | Fractional Flow Reserve computed tomography (FFRct) |
